|
English
|
正體中文
|
简体中文
|
2817371
|
|
???header.visitor??? :
27744635
???header.onlineuser??? :
353
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"millward m"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer
|
Woodford R;Loh Y;Lee J;Cooper W;Marschner I;Lewis C.R;Millward M;Lord S;Gralla R.J;Chih-Hsin Yang;Mok T;Lee C.K.; Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis C.R; Millward M; Lord S; Gralla R.J; CHIH-HSIN YANG; Mok T; Lee C.K. |
| 國家衛生研究院 |
2002-08 |
Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region
|
Putti, TC; To, KF; Hsu, HC; Chan, ATC; Lai, GM; Tse, G; Lee, YS; Whang-Peng, J; Millward, M; Lin, L; Lin, X; Lee, CS |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
